Comparing Efficacy and Safety of Thrice Daily Versus Twice Daily NovoMix® 30 (Biphasic Insulin Aspart 30) in Subjects With Type 2 Diabetes Inadequately Controlled With Basal Insulin

Clinical trial NCT02582242 · COMPLETED

Trial details

NCT number

NCT02582242

Sponsor

Novo Nordisk A/S

Status

COMPLETED

Phase

Phase 4

Study type

INTERVENTIONAL

Start date

2015-10-19

Primary completion

2017-03-18

Enrollment

437

View on ClinicalTrials.gov